Pfizer’s 20-Valent Vaccine And Prevnar Successor Succeeds In Phase III

The company still plans to file 20vPnC for US FDA approval by the end of 2020 after the pneumococcal vaccine was non-inferior to Prevnar and to Pneumovax on six additional serotypes in older patients.

microscope — Pfizer's 20vPnC was non-inferior to its Prevnar 13 vaccine

Pfizer Inc.’s 20-valent pneumococcal conjugated vaccine known as 20vPnC – a follow-up to the company’s blockbuster Prevnar 13 – is getting to the end of its path to patients after proving non-inferior to the predecessor product in a Phase III clinical trial.

Pfizer said when it announced top-line results from the trial on 18 March that it remains on track to file a biologic license application (BLA) with the US Food and Drug Administration for 20vPnC before the end of 2020. The new vaccine will extend an important franchise based on the success of Prevnar 13, which generated $5.8bn in 2018 revenue and $5.85bn in 2019 as the company’s top-selling product

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

06 May 2025

• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.